Recent studies have shown promising results in using CAR-T cell therapy to shrink aggressive brain tumors. Small clinical trials demonstrated the effectiveness and safety of this modified therapy in treating early-stage brain cancer, with some patients experiencing significant tumor reduction after treatment. The FDA has expressed some concerns regarding the safety of CAR-T therapy for early-stage patients, particularly in relation to cancer medicines from Johnson & Johnson and Bristol Myers Squibb. Researchers are exploring new strategies, such as targeting two associated proteins with CAR T cell therapy, to further improve the treatment of brain tumors.
A FDA panel voted in favor of expanding use of CAR-T therapy in multiple myeloma, despite concerns about side effects. https://t.co/s8XYCfPiHW
Scientists use new strategy to successfully shrink tumors in early brain cancer trials. https://t.co/uEzE6dCW0Z Click the image to read more:
Early results from a Phase I clinical trial suggest that using CAR T cell therapy to target two brain tumor-associated proteins. The results could hold promise as a strategy for reducing solid tumor growth in patients with glioblastoma. Read more: https://t.co/t7MlAuHNXO
Brain cancers like glioblastoma are often a death sentence, says @lisamjarvis. But researchers have finally found a way to shrink those tumors https://t.co/Erc5TQhJai via @opinion
Brain cancers like glioblastoma are often a death sentence, says @lisamjarvis. But researchers have finally found a way to shrink those tumors https://t.co/1biVYVQZiS
An FDA advisory committee voted on Friday that the benefits of two CAR-T therapies, Carvykti and Abecma, outweigh their risks in earlier-stage multiple myeloma patients. Carvykti: 11-0 Abecma: 8-3 https://t.co/yWpiwAtvBY
A panel of expert advisers to the FDA voted in favor of expanding the use of CAR-T therapy in blood cancer, despite concerns about side effects. https://t.co/6DiMJn2Pm5
FDA advisers back CAR-T therapies in blood cancer, despite safety concerns https://t.co/MMQM0u1WZ2 via @statnews
FDA advisers back CAR-T therapies in blood cancer, despite safety concerns https://t.co/I78tsGAf0m
FDA advisers back CAR-T therapies in blood cancer, despite safety concerns https://t.co/YtalZLGDij via @damiangarde $JNJ $LEGN $BMY $TSVT
An FDA advisory committee voted unanimously on Friday that the benefits of Johnson & Johnson and Legend Biotech’s CAR-T therapy Carvykti outweigh its risks in earlier-stage multiple myeloma patients. https://t.co/Wen7V7W0kN
US FDA panel unanimously backs expanded use of J&J's CAR-T therapy https://t.co/6ym07yYs2B https://t.co/af4Jij0t0f
CAR-T treatments have shown promise in the way they can reprogram a patient's immune cells to attack cancer cells but are pricey and have been flagged before for safety concerns. https://t.co/bwsmJUfB6d
While CAR-T treatments from Bristol Myers Squibb's Celgene Corp. and J&J's Janssen Biotech each improved progression-free survival in myeloma trials, FDA in briefing documents flagged concerns about an increased risk of early death from adverse events. https://t.co/F7spdVDSVb
Safety risks hang over CAR-T therapies for myeloma https://t.co/heTqeDIgTo @TreedinDC
Early results from an ongoing Phase I clinical trial suggest that using CAR T cell therapy to target two brain tumor-associated proteins could hold promise as a strategy for reducing solid tumor growth in patients with recurrent glioblastoma. Learn more: https://t.co/4E76pq4Zsc
BREAKING: @US_FDA Approves Tislelizumab for Advanced or Metastatic ESCC After Chemotherapy #esocsm #oncology https://t.co/CHlrBg83mJ https://t.co/SzzaIsXw2G
New studies offer hope that CAR-T can eventually be used to treat an incurable and deadly type of brain cancer. https://t.co/IB28K2hn7K
Cell therapy appears to shrink aggressive brain tumors https://t.co/tgg2AapGJQ https://t.co/tgg2AapGJQ
Targeting two associated proteins with CAR T cell therapy rather than one shows promise as a strategy for shrinking brain tumors, according to a clinical trial by researchers at @PennMedicine. https://t.co/LoZK8lkaPf
Some very exciting, but very early, studies this week suggest that CAR-T cell therapies can help shrink aggressive brain tumors. @endpts first reported this back in November when preliminary results were announced at a medical meeting. Read more here: https://t.co/fpm3TidHKM
CAR T-Cell Therapy Successfully Used to Treat Brain Tumors Researchers report the first-ever chimeric antigen receptor CAR T-cell treatment of recurrent brain tumors delivered directly to the tumor. Learn more: https://t.co/MUZM3eOqF9
Three patients with the most aggressive form of brain cancer had their tumors shrink dramatically after a single infusion of a new form of CAR-T cell therapy, according to a study published Wednesday in the New England Journal of Medicine. https://t.co/gW8OloJGTy
Is CAR-T safe for early-stage patients? FDA reviewers have some concerns, according to documents related to a pair of cancer medicines from Johnson & Johnson and Bristol Myers Squibb. https://t.co/i1x9YQyHIz
Small studies offer hope CAR-T can fight an aggressive brain cancer https://t.co/wv9UZdytyq via @statnews
A new strategy to attack aggressive #brainCancer shrank tumors in two early tests @nejm @NatureMedicine https://t.co/m3LNMyjJ2J
A modified version of CAR-T therapy, which is used to treat leukemia and lymphoma, was found to be safe in two small, early clinical trials. https://t.co/x8QMJVIJjk
Scientists use new strategy to successfully shrink tumors in early brain cancer trials https://t.co/A0YRFTxyeE